Daniel A. Eckert Joins Tensentric’s Board of Directors

Tensentric LLC has recruited Daniel A. Eckert to its Board of Directors.

“We are delighted to welcome Dan to Tensentric’s Board of Directors. His deep experience across the healthcare and medical products sectors will be invaluable as we continue scaling our business and building on our strong position in the medical device, IVD, life sciences, and cell and gene therapy markets,” Tensentric CEO Cathy Falbo said.

Eckert has served as CEO, president, chief operating officer, and director of multiple private and publicly traded companies ranging in size from $10 million to more than $2 billion in revenue. His leadership spans venture-backed, private equity-backed, and publicly traded businesses across distribution, medical products, healthcare IT, and laboratory diagnostics. Notably, he led the $1 billion-plus clinical diagnostics division of Thermo Fisher Scientific; LABSCO, a $400 million business backed by Frazier Healthcare (acquired by McKesson in 2016); and StatLab, a $100 million anatomic pathology manufacturer and distributor backed by Cressey & Company (acquired by Audax and Linden Capital in 2020). He currently is chairman and CEO of Aqueous Health, a direct-to-consumer diagnostics company he founded in 2023.

“I am excited to partner with Cathy and the Tensentric team to deliver design and manufacturing solutions to leading and emerging healthcare device manufacturers. We believe Tensentric is uniquely positioned to provide customized product design and development solutions to support the growth strategies of these companies,” Eckert stated.

Based in Boulder, Colo., Tensentric provides outsourced design, engineering, prototyping, and assembly services for medical technology, in-vitro diagnostic, and life sciences companies. Since its founding in 2009, the company has established itself as a leading contract development partner, known for its differentiated team of engineers and experience working on cutting-edge development projects.